All In Biotech

Free tool

FAERS Monitor: Eucrisa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 207695 or its brand name (Eucrisa, Crisaborole). Reports on generic versions are filed under their own applications.

Reports

9,605

Serious

734

8% of reports

Hospitalization

158

Death reported

25

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,995
  • application site pain1,417
  • burning sensation987
  • off label use759
  • condition aggravated711
  • pruritus662
  • rash622
  • pain530
  • eczema469
  • dermatitis atopic455
  • erythema376
  • product use in unapproved indication341
  • dry skin273
  • drug hypersensitivity262
  • drug ineffective for unapproved indication243

Reports by year received

View as table
YearReports
20131
20141
20171,288
20182,074
20191,981
20201,051
2021497
2022941
2023675
2024528
2025371
2026197

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,554 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
application site painSignal1,417150.5143.1196,937
burning sensationSignal98731.329.428,561
eczemaSignal46919.818.18,296
dermatitis atopicSignal45519.117.47,716
drug ineffective for unapproved indicationSignal2439.78.61,892
condition aggravatedSignal7115.14.82,389
dry skinSignal2734.54.0739
erythemaSignal3764.03.6854
pruritusSignal6623.83.51,372
drug ineffectiveSignal1,9953.33.23,440
rashSignal6223.12.9916
product use in unapproved indicationSignal3413.02.7462
drug hypersensitivitySignal2623.02.6342
off label use7591.91.8336
pain5301.91.7228

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.